Maxim Group analyst Jason McCarthy maintained a Buy rating on Atossa Therapeutics (ATOS – Research Report) on March 25 and set a price target of $4.00.
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Atossa Therapeutics’ strategic advancements and potential in the oncology field. The company’s focus on moving endoxifen into a program for metastatic breast cancer is seen as a strategic move, given the significant unmet medical needs in this area. The potential for a more efficient regulatory pathway enhances the attractiveness of this endeavor, especially considering the encouraging early clinical data that demonstrate endoxifen’s efficacy in extending progression-free survival and maintaining stable disease in patients.
Furthermore, the positive results from the P2 EVANGELINE and Karisma-Endoxifen studies underscore the promise of endoxifen in treating breast cancer and reducing mammographic breast density. These studies have shown favorable outcomes in terms of tumor suppression and breast density reduction, which are critical factors in breast cancer treatment and prevention. The financial outlook is also promising, with a strong cash position providing runway into 2027, and a valuation model that anticipates the commercial launch of endoxifen in 2028, supporting the $4.00 price target. These elements collectively form the basis for McCarthy’s optimistic Buy rating.
McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Medicus Pharma Ltd, and Actinium Pharmaceuticals. According to TipRanks, McCarthy has an average return of -18.6% and a 26.41% success rate on recommended stocks.
In another report released on March 25, H.C. Wainwright also maintained a Buy rating on the stock with a $7.00 price target.